Hagn G, Cho A, Zila N, Sterniczky B, Jantschitsch C, Dong D
Inflamm Res. 2025; 74(1):40.
PMID: 39945859
PMC: 11825557.
DOI: 10.1007/s00011-025-02007-6.
Liu D, Liu J, Li Y, Du L, Cao Q, Yang L
iScience. 2024; 27(12):111290.
PMID: 39618500
PMC: 11607605.
DOI: 10.1016/j.isci.2024.111290.
Jacobson J
Cell Biochem Biophys. 2021; 79(3):509-516.
PMID: 34370281
PMC: 8551086.
DOI: 10.1007/s12013-021-01022-8.
McGowan E, Haddadi N, Nassif N, Lin Y
Int J Mol Sci. 2020; 21(19).
PMID: 33003377
PMC: 7583882.
DOI: 10.3390/ijms21197189.
Marciniak A, Camp S, Garcia J, Polt R
Bioorg Med Chem Lett. 2018; 28(23-24):3585-3591.
PMID: 30409535
PMC: 6430570.
DOI: 10.1016/j.bmcl.2018.10.042.
Sphingosine 1-Phosphate Receptors: Do They Have a Therapeutic Potential in Cardiac Fibrosis?.
Vestri A, Pierucci F, Frati A, Monaco L, Meacci E
Front Pharmacol. 2017; 8:296.
PMID: 28626422
PMC: 5454082.
DOI: 10.3389/fphar.2017.00296.
Mammalian sphingosine kinase (SphK) isoenzymes and isoform expression: challenges for SphK as an oncotarget.
Hatoum D, Haddadi N, Lin Y, Nassif N, McGowan E
Oncotarget. 2017; 8(22):36898-36929.
PMID: 28415564
PMC: 5482707.
DOI: 10.18632/oncotarget.16370.
Sphingosine 1-Phosphate Receptor Modulators and Drug Discovery.
Park S, Im D
Biomol Ther (Seoul). 2016; 25(1):80-90.
PMID: 28035084
PMC: 5207465.
DOI: 10.4062/biomolther.2016.160.
Attenuation of experimental autoimmune neuritis with locally administered lovastatin-encapsulating poly(lactic-co-glycolic) acid nanoparticles.
Langert K, Goshu B, Stubbs Jr E
J Neurochem. 2016; 140(2):334-346.
PMID: 27861905
PMC: 5225029.
DOI: 10.1111/jnc.13892.
Biomarkers of Guillain-Barré Syndrome: Some Recent Progress, More Still to Be Explored.
Wang Y, Sun S, Zhu J, Cui L, Zhang H
Mediators Inflamm. 2015; 2015:564098.
PMID: 26451079
PMC: 4588351.
DOI: 10.1155/2015/564098.
The S1P1 receptor-selective agonist CYM-5442 reduces the severity of acute GVHD by inhibiting macrophage recruitment.
Cheng Q, Ma S, Lin D, Mei Y, Gong H, Lei L
Cell Mol Immunol. 2014; 12(6):681-91.
PMID: 25088224
PMC: 4716627.
DOI: 10.1038/cmi.2014.59.
Chemical and genetic tools to explore S1P biology.
Cahalan S
Curr Top Microbiol Immunol. 2014; 378:55-83.
PMID: 24728593
PMC: 7120161.
DOI: 10.1007/978-3-319-05879-5_3.
New strategies in the management of Guillain-Barré syndrome.
Xiao J, Simard A, Shi F, Hao J
Clin Rev Allergy Immunol. 2013; 47(3):274-88.
PMID: 24057598
DOI: 10.1007/s12016-013-8388-5.
Selective deletion of the endothelial sphingosine-1-phosphate 1 receptor exacerbates kidney ischemia-reperfusion injury.
Ham A, Kim M, Kim J, Brown K, Fruttiger M, DAgati V
Kidney Int. 2013; 85(4):807-23.
PMID: 24025642
PMC: 3952061.
DOI: 10.1038/ki.2013.345.
Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond.
Kunkel G, Maceyka M, Milstien S, Spiegel S
Nat Rev Drug Discov. 2013; 12(9):688-702.
PMID: 23954895
PMC: 3908769.
DOI: 10.1038/nrd4099.
S1P(1) receptor modulation with cyclical recovery from lymphopenia ameliorates mouse model of multiple sclerosis.
Gonzalez-Cabrera P, Cahalan S, Nguyen N, Sarkisyan G, Leaf N, Cameron M
Mol Pharmacol. 2011; 81(2):166-74.
PMID: 22031473
PMC: 3263953.
DOI: 10.1124/mol.111.076109.
Sphingosine-1-phosphate signaling and its role in disease.
Maceyka M, Harikumar K, Milstien S, Spiegel S
Trends Cell Biol. 2011; 22(1):50-60.
PMID: 22001186
PMC: 3253987.
DOI: 10.1016/j.tcb.2011.09.003.
Regulation of mammalian physiology, development, and disease by the sphingosine 1-phosphate and lysophosphatidic acid receptors.
Blaho V, Hla T
Chem Rev. 2011; 111(10):6299-320.
PMID: 21939239
PMC: 3216694.
DOI: 10.1021/cr200273u.
The strategies used for treatment of experimental autoimmune neuritis (EAN): a beneficial effect of glatiramer acetate administered intraperitoneally.
Aronovich R, Katzav A, Chapman J
Clin Rev Allergy Immunol. 2011; 42(2):181-8.
PMID: 21234710
DOI: 10.1007/s12016-010-8246-7.